Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2025
Description
DelveInsight’s, “Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Chemotherapy Induced Nausea and Vomiting pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Chemotherapy Induced Nausea and Vomiting: Overview
Chemotherapy-induced nausea and vomiting (CINV) is a distressing side effect experienced by many cancer patients undergoing chemotherapy treatment. It occurs due to the toxic effects of chemotherapy drugs on the gastrointestinal tract and the central nervous system. The severity and duration of CINV can vary widely among patients, with some experiencing mild symptoms while others suffer from debilitating nausea and vomiting. These symptoms can significantly impact patients' quality of life, leading to decreased appetite, weight loss, dehydration, and disruptions in daily activities.
The underlying causes of CINV are complex and multifactorial. Chemotherapy drugs can directly stimulate areas of the brain responsible for nausea and vomiting, such as the chemoreceptor trigger zone and the vomiting center. Additionally, chemotherapy-induced damage to the lining of the gastrointestinal tract can contribute to nausea and vomiting symptoms. Individual patient factors, such as age, gender, previous history of motion sickness or nausea, and genetic variations, can also influence the susceptibility to CINV. Certain chemotherapy drugs are more likely to cause CINV than others, and the risk may vary based on the dose and schedule of administration.
Diagnosing CINV primarily involves evaluating the patient's reported symptoms and medical history. Healthcare providers will inquire about the type of chemotherapy drugs received, the dosage, and the timing of symptoms relative to treatment administration. Various assessment tools, including nausea and vomiting scales, may be used to quantify the severity of symptoms and monitor their progression over time. It's essential for healthcare providers to maintain open communication with patients regarding their symptoms to tailor treatment plans accordingly and provide appropriate support.
Treatment strategies for CINV aim to prevent or minimize symptoms, improve patients' quality of life, and ensure adherence to chemotherapy regimens. Prophylactic antiemetic medications are commonly prescribed before and after chemotherapy sessions to reduce the risk of CINV. These may include serotonin receptor antagonists, neurokinin-1 receptor antagonists, corticosteroids, and other supportive medications. Non-pharmacological interventions such as dietary modifications, acupuncture, acupressure, and relaxation techniques may also be recommended as adjunct therapies. Patient education about CINV management strategies and proactive symptom monitoring are crucial components of comprehensive care for cancer patients undergoing chemotherapy.
""Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chemotherapy Induced Nausea and Vomiting pipeline landscape is provided which includes the disease overview and Chemotherapy Induced Nausea and Vomiting treatment guidelines. The assessment part of the report embraces, in depth Chemotherapy Induced Nausea and Vomiting commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chemotherapy Induced Nausea and Vomiting collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Chemotherapy Induced Nausea and Vomiting report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chemotherapy Induced Nausea and Vomiting Emerging Drugs
Further product details are provided in the report……..
Chemotherapy Induced Nausea and Vomiting: Therapeutic Assessment
This segment of the report provides insights about the different Chemotherapy Induced Nausea and Vomiting drugs segregated based on following parameters that define the scope of the report, such as:
Chemotherapy Induced Nausea and Vomiting: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chemotherapy Induced Nausea and Vomiting therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chemotherapy Induced Nausea and Vomiting drugs.
Chemotherapy Induced Nausea and Vomiting Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Chemotherapy Induced Nausea and Vomiting: Overview
Chemotherapy-induced nausea and vomiting (CINV) is a distressing side effect experienced by many cancer patients undergoing chemotherapy treatment. It occurs due to the toxic effects of chemotherapy drugs on the gastrointestinal tract and the central nervous system. The severity and duration of CINV can vary widely among patients, with some experiencing mild symptoms while others suffer from debilitating nausea and vomiting. These symptoms can significantly impact patients' quality of life, leading to decreased appetite, weight loss, dehydration, and disruptions in daily activities.
The underlying causes of CINV are complex and multifactorial. Chemotherapy drugs can directly stimulate areas of the brain responsible for nausea and vomiting, such as the chemoreceptor trigger zone and the vomiting center. Additionally, chemotherapy-induced damage to the lining of the gastrointestinal tract can contribute to nausea and vomiting symptoms. Individual patient factors, such as age, gender, previous history of motion sickness or nausea, and genetic variations, can also influence the susceptibility to CINV. Certain chemotherapy drugs are more likely to cause CINV than others, and the risk may vary based on the dose and schedule of administration.
Diagnosing CINV primarily involves evaluating the patient's reported symptoms and medical history. Healthcare providers will inquire about the type of chemotherapy drugs received, the dosage, and the timing of symptoms relative to treatment administration. Various assessment tools, including nausea and vomiting scales, may be used to quantify the severity of symptoms and monitor their progression over time. It's essential for healthcare providers to maintain open communication with patients regarding their symptoms to tailor treatment plans accordingly and provide appropriate support.
Treatment strategies for CINV aim to prevent or minimize symptoms, improve patients' quality of life, and ensure adherence to chemotherapy regimens. Prophylactic antiemetic medications are commonly prescribed before and after chemotherapy sessions to reduce the risk of CINV. These may include serotonin receptor antagonists, neurokinin-1 receptor antagonists, corticosteroids, and other supportive medications. Non-pharmacological interventions such as dietary modifications, acupuncture, acupressure, and relaxation techniques may also be recommended as adjunct therapies. Patient education about CINV management strategies and proactive symptom monitoring are crucial components of comprehensive care for cancer patients undergoing chemotherapy.
""Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chemotherapy Induced Nausea and Vomiting pipeline landscape is provided which includes the disease overview and Chemotherapy Induced Nausea and Vomiting treatment guidelines. The assessment part of the report embraces, in depth Chemotherapy Induced Nausea and Vomiting commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chemotherapy Induced Nausea and Vomiting collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Chemotherapy Induced Nausea and Vomiting R&D. The therapies under development are focused on novel approaches to treat/improve Chemotherapy Induced Nausea and Vomiting.
This segment of the Chemotherapy Induced Nausea and Vomiting report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chemotherapy Induced Nausea and Vomiting Emerging Drugs
- Fosnetupitant: Helsinn Healthcare SA
- APD403: Acacia Pharma
- CAM2047: Camurus
Further product details are provided in the report……..
Chemotherapy Induced Nausea and Vomiting: Therapeutic Assessment
This segment of the report provides insights about the different Chemotherapy Induced Nausea and Vomiting drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Chemotherapy Induced Nausea and Vomiting
- There are approx. 8+ key companies which are developing the therapies for Chemotherapy Induced Nausea and Vomiting. The companies which have their Chemotherapy Induced Nausea and Vomiting drug candidates in the most advanced stage, i.e. phase III include, Helsinn Healthcare SA.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Chemotherapy Induced Nausea and Vomiting: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chemotherapy Induced Nausea and Vomiting therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chemotherapy Induced Nausea and Vomiting drugs.
Chemotherapy Induced Nausea and Vomiting Report Insights
- Chemotherapy Induced Nausea and Vomiting Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chemotherapy Induced Nausea and Vomiting drugs?
- How many Chemotherapy Induced Nausea and Vomiting drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chemotherapy Induced Nausea and Vomiting?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chemotherapy Induced Nausea and Vomiting therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chemotherapy Induced Nausea and Vomiting and their status?
- What are the key designations that have been granted to the emerging drugs?
- Helsinn Healthcare SA
- Acacia Pharma
- Camurus
- Benuvia Therapeutics
- Aphios Corporation
- Aphios Corporation
- Zhuhai Beihai Biotech Co., Ltd.
- Fosnetupitant
- APD403
- CAM2047
- Ondansetron sublingual
- Zindol
- Research programme: Cannabinoid Nano therapeutics
- BH006
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Chemotherapy Induced Nausea and Vomiting : Overview
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Chemotherapy Induced Nausea and Vomiting – DelveInsight’s Analytical Perspective
- Late Stage Products (Registration)
- Comparative Analysis
- Fosnetupitant: Helsinn Healthcare SA
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- APD403: Acacia Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- CAM2047: Camurus
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Chemotherapy Induced Nausea and Vomiting Key Companies
- Chemotherapy Induced Nausea and Vomiting Key Products
- Chemotherapy Induced Nausea and Vomiting - Unmet Needs
- Chemotherapy Induced Nausea and Vomiting - Market Drivers and Barriers
- Chemotherapy Induced Nausea and Vomiting - Future Perspectives and Conclusion
- Chemotherapy Induced Nausea and Vomiting Analyst Views
- Chemotherapy Induced Nausea and Vomiting Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
